{
    "clinical_study": {
        "@rank": "129317", 
        "arm_group": [
            {
                "arm_group_label": "Placebo + Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Two placebos are given for 84 days."
            }, 
            {
                "arm_group_label": "Progesterone + Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Progesterone (200 mg twice daily) and a placebo are given"
            }, 
            {
                "arm_group_label": "Progesterone + Atomoxetine", 
                "arm_group_type": "Active Comparator", 
                "description": "Progesterone (200 mg twice daily) plus atomoxetine (60 mg once daily) are given."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the role of progesterone (a hormone found in both\n      men and women) and atomoxetine (a medication that has been shown to decrease impulsivity) on\n      stopping cocaine use.  The study will examine whether the medications, in combination with\n      behavior therapy will decrease cocaine use, cigarette smoking, withdrawal symptoms,\n      impulsivity and stress."
        }, 
        "brief_title": "Progesterone and Atomoxetine for Cocaine Cessation", 
        "condition": [
            "Cocaine Addiction", 
            "Smoking Addiction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Smoking", 
                "Behavior, Addictive", 
                "Cocaine-Related Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females and males between 18 and 40 years-of-age;\n\n          -  Understand the study procedures and provide written informed consent;\n\n          -  Meet DSM-IV criteria for cocaine and nicotine dependence;\n\n          -  Minimum of cocaine use 6 days/months over last 3 months;\n\n          -  Minimum of 5 cigarettes/day for last twelve months;\n\n          -  Stable psychiatric status;\n\n          -  Stable medical status; Willing to use double-barrier contraception method if sexually\n             active and not surgically sterilized;\n\n          -  Regular menstrual cycles (for females);\n\n          -  No contraindications to progesterone or atomxetine treatment;\n\n          -  Ability to participate fully in research elements for the duration of the trial.\n\n        Exclusion Criteria:\n\n          -  DSM-IV diagnoses for current or lifetime psychotic disorders (unless substance\n             induced), bipolar disorder, ADHD and other current substance dependence (except\n             nicotine dependence, or alcohol or cannabis dependence not exhibiting withdrawal or\n             other features requiring medical attention);\n\n          -  Currently using nicotine pharmacotherapy preparations;\n\n          -  history of thromboembolic events, diabetes, stroke, heart disease;\n\n          -  Other prescribed psychotropic medications;\n\n          -  Currently pregnant or nursing;\n\n          -  Liver enzyme levels three times normal limits;\n\n          -  Previous treatment with or adverse response to progesterone or atomoxetine;\n\n          -  Serious suicide attempt within preceding 2 years;\n\n          -  Current use of exogenous hormones, efavirenz, red clover, monoamine oxidase\n             inhibitors, albuterol, amoxapine, amitriptyline, dibenzepin hydrochloride, opipramol\n             hydrochloride, lofepramine, nortriptyline, desipramine, clomipramine hydrochloride,\n             protriptyline, trimipramine, dothiepin, imipramine, lorcaserin, quinidine,\n             fluoxetine, praoxetine mesylate, clobazam, ranolazine, ketoconazole and/or CYP2D6 or\n             CYP3A4 inhibitors;\n\n          -  Conditions contraindicated to progesterone treatment (including, but not limited to,\n             thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding\n             disorders, heart disease, diabetes, history of stroke, allergy to peanuts,\n             hypersensitive to progesterone and liver dysfunction).\n\n          -  History of pheochromotytoma or narrow angle glaucoma,\n\n          -  Current hypertension, tachycardia or clinically relevant ECG abnormalites;\n\n          -  Allergy to peanuts,\n\n          -  Current suicidality or need for emergency psychiatric treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741376", 
            "org_study_id": "1P50DA033942-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Progesterone + Placebo", 
                    "Progesterone + Atomoxetine"
                ], 
                "description": "Progesterone 200 mg twice daily", 
                "intervention_name": "Progesterone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Progesterone + Atomoxetine", 
                "description": "60 mg once a day", 
                "intervention_name": "Atomoxetine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Progesterone", 
                "Atomoxetine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 30, 2012", 
        "number_of_arms": "3", 
        "official_title": "Progesterone and Atomoxetine for Cocaine Cessation", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Urine Test", 
            "measure": "Cocaine Cessation", 
            "safety_issue": "No", 
            "time_frame": "Days 1 to 86"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741376"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Self report of the following subjective questionnaires: (1) Behavioral Inhibition Activation Scales, (2) Barratt Impulsivity Scale, and (3) Brief Self Control Scale.", 
            "measure": "Impulsivity", 
            "safety_issue": "No", 
            "time_frame": "Days 1 to 86"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}